Vaxcyte Q3 net loss $212.8M; cash $2.67B; VAX-31 adult pivotal study start Dec 2025

Vaxcyte, Inc.

2025-Q3 EPS reported -$3.83

Net loss of $212.8M for Q3 2025 vs $103.1M in Q3 2024; R&D expenses $209.9M, up from $116.9M.
Cash, cash equivalents and investments $2.67B as of Sept 30, 2025, expected to fund operations into mid-2028.
Final VAX-24 infant Phase 2 data show robust dose-dependent immune responses, validating higher VAX-31 doses.
VAX-31 adult pivotal non-inferiority study to start Dec 2025; topline data expected in 2026.
Up to $1B fill-finish agreement with Thermo Fisher in North Carolina for long-term U.S. commercial supply.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.